Heart:射血分数保留vs.射血分数降低心衰患者的预后和NT-proBNP

2019-04-13 xiangting MedSci原创

这项研究强调并证实了NT-proBNP水平在HFpEF患者中可以提供与HFrEF相同的相对风险信息。

这项研究评估了因急性失代偿性心衰住院的射血分数保留(HFpEF)vs射血分数降低(HFrEF)心衰患者N-末端B型利钠肽(NT-proBNP)水平变化绝对值和百分比的预后意义。

左心室射血分数≥50%的患者被归类为HFpEF(n=283),而<40%的患者被归类为HFrEF(n=776)。通过多因素调整的Cox回归分析,在HFpEF和HFrEF患者中分别评估了NT-proBNP水平变化的绝对值和百分比对出院后6个月全因死亡率的预后价值。比较了不同心衰组间的合并症。

出院NT-proBNP水平可以预测结局,HFpEF与HFrEF组相似:NT-proBNP水平任意增加2.7因子,HFpEF组的死亡率HR为2.14(95%CI为1.48至3.09),HFrEF为1.96(95%CI为1.60至2.40)。与参考组NT-proBNP水平降低>60%的死亡率相比,NT-proBNP降低≤30%(HFpEF和HFrEF分别为HR 4.60,95%CI 1.47至14.40和HR 3.36,95%CI 1.93至5.85)和降低>30%-60%(分别为HR 3.28,95%CI 1.07至10.12和HR 1.79,95%CI 0.99至3.26)的死亡率预测概率相当。HFpEF患者的预后相关合并症比出院NT-proBNP低的HFrEF患者常见(≤3000pg/mL),但在出院NT-proBNP高的患者中并非如此(>3000pg/mL)。

这项研究强调并证实了NT-proBNP水平在HFpEF患者中可以提供与HFrEF相同的相对风险信息,合并症在NT-proBNP水平低的HFpEF患者中对预后的影响比HFrEF患者更多。

原始出处:

Khibar Salah. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. Heart. 08 April 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1190228, encodeId=61a1119022861, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Sat Feb 05 06:18:50 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746309, encodeId=bceb1e46309f3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Mon Feb 17 21:54:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289325, encodeId=9bf0128932550, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290354, encodeId=675712903540d, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357162, encodeId=ed4d135e162a5, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373442, encodeId=ed4213e3442e8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449250, encodeId=4d631449250e3, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563082, encodeId=e51f156308287, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602144, encodeId=9d861602144a9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
    2022-02-05 forvalen

    好好学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1190228, encodeId=61a1119022861, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Sat Feb 05 06:18:50 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746309, encodeId=bceb1e46309f3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Mon Feb 17 21:54:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289325, encodeId=9bf0128932550, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290354, encodeId=675712903540d, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357162, encodeId=ed4d135e162a5, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373442, encodeId=ed4213e3442e8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449250, encodeId=4d631449250e3, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563082, encodeId=e51f156308287, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602144, encodeId=9d861602144a9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1190228, encodeId=61a1119022861, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Sat Feb 05 06:18:50 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746309, encodeId=bceb1e46309f3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Mon Feb 17 21:54:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289325, encodeId=9bf0128932550, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290354, encodeId=675712903540d, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357162, encodeId=ed4d135e162a5, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373442, encodeId=ed4213e3442e8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449250, encodeId=4d631449250e3, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563082, encodeId=e51f156308287, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602144, encodeId=9d861602144a9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
    2019-04-15 huiwelcome
  4. [GetPortalCommentsPageByObjectIdResponse(id=1190228, encodeId=61a1119022861, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Sat Feb 05 06:18:50 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746309, encodeId=bceb1e46309f3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Mon Feb 17 21:54:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289325, encodeId=9bf0128932550, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290354, encodeId=675712903540d, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357162, encodeId=ed4d135e162a5, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373442, encodeId=ed4213e3442e8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449250, encodeId=4d631449250e3, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563082, encodeId=e51f156308287, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602144, encodeId=9d861602144a9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
    2019-04-15 mjldent
  5. [GetPortalCommentsPageByObjectIdResponse(id=1190228, encodeId=61a1119022861, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Sat Feb 05 06:18:50 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746309, encodeId=bceb1e46309f3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Mon Feb 17 21:54:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289325, encodeId=9bf0128932550, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290354, encodeId=675712903540d, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357162, encodeId=ed4d135e162a5, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373442, encodeId=ed4213e3442e8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449250, encodeId=4d631449250e3, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563082, encodeId=e51f156308287, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602144, encodeId=9d861602144a9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
    2019-04-15 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1190228, encodeId=61a1119022861, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Sat Feb 05 06:18:50 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746309, encodeId=bceb1e46309f3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Mon Feb 17 21:54:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289325, encodeId=9bf0128932550, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290354, encodeId=675712903540d, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357162, encodeId=ed4d135e162a5, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373442, encodeId=ed4213e3442e8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449250, encodeId=4d631449250e3, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563082, encodeId=e51f156308287, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602144, encodeId=9d861602144a9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1190228, encodeId=61a1119022861, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Sat Feb 05 06:18:50 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746309, encodeId=bceb1e46309f3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Mon Feb 17 21:54:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289325, encodeId=9bf0128932550, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290354, encodeId=675712903540d, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357162, encodeId=ed4d135e162a5, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373442, encodeId=ed4213e3442e8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449250, encodeId=4d631449250e3, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563082, encodeId=e51f156308287, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602144, encodeId=9d861602144a9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1190228, encodeId=61a1119022861, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Sat Feb 05 06:18:50 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746309, encodeId=bceb1e46309f3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Mon Feb 17 21:54:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289325, encodeId=9bf0128932550, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290354, encodeId=675712903540d, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357162, encodeId=ed4d135e162a5, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373442, encodeId=ed4213e3442e8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449250, encodeId=4d631449250e3, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563082, encodeId=e51f156308287, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602144, encodeId=9d861602144a9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
    2019-04-15 slcumt
  9. [GetPortalCommentsPageByObjectIdResponse(id=1190228, encodeId=61a1119022861, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/b39c8bc0ab334969ba4ccc08e7a6cd94/c4e41798ef27449aa31ad740c9b13062.jpg, createdBy=5ff35133022, createdName=forvalen, createdTime=Sat Feb 05 06:18:50 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746309, encodeId=bceb1e46309f3, content=<a href='/topic/show?id=699a46801f4' target=_blank style='color:#2F92EE;'>#射血分数保留#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46801, encryptionId=699a46801f4, topicName=射血分数保留)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c84e35706999, createdName=lixiao3338, createdTime=Mon Feb 17 21:54:00 CST 2020, time=2020-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289325, encodeId=9bf0128932550, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290354, encodeId=675712903540d, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357162, encodeId=ed4d135e162a5, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373442, encodeId=ed4213e3442e8, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449250, encodeId=4d631449250e3, content=<a href='/topic/show?id=2ff746814f0' target=_blank style='color:#2F92EE;'>#射血分数降低#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46814, encryptionId=2ff746814f0, topicName=射血分数降低)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50105466425, createdName=lmm399, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563082, encodeId=e51f156308287, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602144, encodeId=9d861602144a9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 15 01:54:00 CST 2019, time=2019-04-15, status=1, ipAttribution=)]
    2019-04-15 sunylz

相关资讯

JACC:经导管二尖瓣修复患者房颤的患病率以及对1年预后的影响

接受经导管MV修复的患者中AF很常见,并与1年的临床结局较差相关。

JACC:医保政策对心衰患者再住院率的影响

医疗保险医院减少再入院计划导致主要诊断为心力衰竭(HF)的住院后再入院人数减少,且心衰患者很少因为其他原因再住院。本研究旨在比较主要心衰住院和其他心衰住院后经医疗保险风险调整的30天再入院的趋势。本研究纳入了2008-2015年12973853名主要或次要因为心衰住院的医保患者,住院患者分为以下几类:主要因心衰住院的,主要急性心肌梗死或肺炎继发性心力衰竭住院的,和其他原因继发心衰住院的。在2010

JACC:IL-1β对急性失代偿心衰患者预后的预测价值

可溶性ST2(sST2)是白介素(IL)-1受体样-1的一种形式,可以预测急性失代偿心衰(ADHF)的风险。 IL-1β是一个对心肌重塑和功能有害的炎症因子,急性心梗后 IL-1β抑制剂的应用可以改善预后,然而, IL-1β与ADHF和sST2的相关性尚不明确。本研究的目的旨在评估IL-1β与sST2的相关性,及其对ADHF患者的预后价值。本研究纳入了316名因ADHF住院的患者(平均年龄为72±

2019 HFSA共识声明:心衰患者的营养,肥胖和恶病质

2019年3月,美国心衰学会(HFSA)发布了心衰患者的营养,肥胖和恶病质共识,心衰患者的饮食指导传统上侧重于限制钠和液体的摄入,但是心衰患者的饮食质量往往很差。本文主要目的是综合有关饮食质量、微生物补充、以及肥胖和恶病质管理的的现有证据,提供相关的共识建议。

扩心病心衰难以控制?这个治疗方案事半功倍!

患者于入院前10年无明显诱因出现心累、气促,劳累后加重,伴胸闷、气短、夜间高枕卧位,偶伴咳嗽,以干咳为主,双下肢凹陷性水肿,患者多次在当地门诊及社区医院住院治疗,诊断为“慢性心力衰竭、扩张型心肌病”,并给予药物治疗(具体不详)。以上症状反复发生,患者自觉症状好转后自行停药,症状加重时自行到诊所购买“利尿剂”(具体不详)进行处理。

心衰合并急性肾损伤,这个治疗方案值得推荐!

患者女,65岁,因“反复头晕20余年,再发伴咳痰、胸闷气促2天”入院。